Patents by Inventor Carrie A. BOWEN

Carrie A. BOWEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MDMA FOR TREATMENT OF STRESS-RELATED DISORDERS
    Publication number: 20240082212
    Abstract: Methods of treating a stress-related disease or disorder such as PTSD, decreasing side effects of 3,4-methylenedioxy-methamphetamine (MDMA), inducing neurite outgrowth, inducing structural neuroplasticity, or increasing brain-derived neurotrophic factor (BDNF) levels, comprising administering to a subject effective amounts of a composition comprising R(?)-3,4-methylenedioxymethamphetamine (R(?)-MDMA) are disclosed. Also disclosed are pharmaceutical compositions comprising R(?)-MDMA and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 8, 2023
    Publication date: March 14, 2024
    Inventors: Glenn Short, Carrie Bowen, Srinivas Rao
  • COMPOSITIONS AND METHODS FOR TREATING HEADACHE OR FACIAL PAIN
    Publication number: 20230310374
    Abstract: The present disclosure provides new methods of treating headache or facial pain with 5-methoxytryptamine or 5-hydroxytryptamine and compositions thereof.
    Type: Application
    Filed: March 29, 2023
    Publication date: October 5, 2023
    Inventors: Srinivas G. RAO, Glenn SHORT, Carrie BOWEN
  • Methods of treating neurological and psychiatric disorders
    Patent number: 11738002
    Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: August 29, 2023
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Carrie A. Bowen, Seth Cabot Hopkins, Colleen M. Synan
  • ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF
    Publication number: 20230129723
    Abstract: The present disclosure provides compositions comprising (R)-MDMA or a pharmaceutically acceptable salt thereof with no or substantially no (S)-MDMA, pharmaceutically acceptable salt thereof, or metabolite thereof. Also provided herein are methods of using the compositions for treating diseases/disorders, e.g., PTSD.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 27, 2023
    Inventors: Glenn SHORT, Carrie BOWEN
  • IBOGAINE COMBINATION TREATMENT
    Publication number: 20230100844
    Abstract: The present disclosure is directed to methods of improving the therapeutic effectiveness and safety profile of ibogaine for the treatment of conditions including, but not limited to, alcoholism, substance abuse disorder, and opioid use disorder.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 30, 2023
    Inventors: Srinivas G. RAO, Glenn SHORT, Carrie BOWEN, Robert BUSBY
  • COMPOSITIONS AND METHODS FOR TREATING HEADACHES
    Publication number: 20230099972
    Abstract: The present disclosure provides new methods of treating headache disorders with 5-methoxytryptamine or 5-hydroxytryptamine and compositions thereof
    Type: Application
    Filed: September 30, 2022
    Publication date: March 30, 2023
    Inventors: Srinivas G. RAO, Glenn SHORT, Carrie BOWEN
  • ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF
    Publication number: 20230097530
    Abstract: The present disclosure provides compositions comprising (R)-MDMA or a pharmaceutically acceptable salt thereof with no or substantially no (S)-MDMA, pharmaceutically acceptable salt thereof, or metabolite thereof. Also provided herein are methods of using the compositions for treating diseases/disorders, e.g., PTSD.
    Type: Application
    Filed: September 30, 2022
    Publication date: March 30, 2023
    Inventors: Glenn SHORT, Carrie BOWEN, Rebecca ARON
  • Heteroaryl-isochroman compounds and uses thereof
    Patent number: 11491133
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: November 8, 2022
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
  • METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20210315859
    Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Inventors: Carrie A. BOWEN, Seth Cabot HOPKINS, Colleen M. SYNAN
  • Compounds and compositions and uses thereof
    Patent number: 11077090
    Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 3, 2021
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Vadim Alexandrov, Carrie A. Bowen, Taleen G. Hanania, Noel Aaron Powell
  • COMPOUNDS AND USES THEREOF
    Publication number: 20210093606
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: August 12, 2020
    Publication date: April 1, 2021
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
  • Compounds and uses thereof
    Patent number: 10780074
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: September 22, 2020
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
  • COMPOUNDS AND USES THEREOF
    Publication number: 20190038594
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: August 1, 2018
    Publication date: February 7, 2019
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L.R. Heffernan, Lee W. Herman, Linghong Xie
  • COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20180028492
    Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed.
    Type: Application
    Filed: July 28, 2017
    Publication date: February 1, 2018
    Inventors: Noel Aaron POWELL, Taleen G. HANANIA, Vadim ALEXANDROV, Carrie A. BOWEN
  • Modulators of opioid receptors and methods of use thereof
    Patent number: 9580409
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., ?-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: February 28, 2017
    Assignee: SUNOVION PHARMACEUTICALS, INC.
    Inventors: Scott Malcolm, Carrie Bowen, Laurence Melnick, Linghong Xie
  • MODULATORS OF OPIOID RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20140288050
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., ?-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: November 7, 2012
    Publication date: September 25, 2014
    Inventors: Scott Malcolm, Carrie Bowen, Laurence Melnick, Linghong Xie